INCR
Price
$1.63
Change
+$0.04 (+2.53%)
Updated
Sep 8, 04:58 PM (EDT)
Capitalization
86.13M
71 days until earnings call
RGC
Price
$13.44
Change
+$0.18 (+1.36%)
Updated
Sep 8, 04:59 PM (EDT)
Capitalization
6.56B
Interact to see
Advertisement

INCR vs RGC

Header iconINCR vs RGC Comparison
Open Charts INCR vs RGCBanner chart's image
Intercure
Price$1.63
Change+$0.04 (+2.53%)
Volume$420
Capitalization86.13M
Regencell Bioscience Holdings
Price$13.44
Change+$0.18 (+1.36%)
Volume$233
Capitalization6.56B
INCR vs RGC Comparison Chart in %
Loading...
INCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INCR vs. RGC commentary
Sep 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCR is a Hold and RGC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 09, 2025
Stock price -- (INCR: $1.58 vs. RGC: $13.26)
Brand notoriety: INCR and RGC are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: INCR: 3% vs. RGC: 19%
Market capitalization -- INCR: $86.13M vs. RGC: $6.56B
INCR [@Pharmaceuticals: Generic] is valued at $86.13M. RGC’s [@Pharmaceuticals: Generic] market capitalization is $6.56B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCR’s FA Score shows that 1 FA rating(s) are green whileRGC’s FA Score has 0 green FA rating(s).

  • INCR’s FA Score: 1 green, 4 red.
  • RGC’s FA Score: 0 green, 5 red.
According to our system of comparison, INCR is a better buy in the long-term than RGC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCR’s TA Score shows that 4 TA indicator(s) are bullish while RGC’s TA Score has 3 bullish TA indicator(s).

  • INCR’s TA Score: 4 bullish, 7 bearish.
  • RGC’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, RGC is a better buy in the short-term than INCR.

Price Growth

INCR (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while RGC (@Pharmaceuticals: Generic) price change was -5.62% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.30%. For the same industry, the average monthly price growth was +9.43%, and the average quarterly price growth was +86.94%.

Reported Earning Dates

INCR is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.30% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGC($6.56B) has a higher market cap than INCR($86.1M). RGC YTD gains are higher at: 10099.918 vs. INCR (-0.629).
INCRRGCINCR / RGC
Capitalization86.1M6.56B1%
EBITDAN/AN/A-
Gain YTD-0.62910099.918-0%
P/E Ratio24.99N/A-
RevenueN/AN/A-
Total CashN/A2.96M-
Total DebtN/A85.7K-
FUNDAMENTALS RATINGS
INCR vs RGC: Fundamental Ratings
INCR
RGC
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
95
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
87100
PRICE GROWTH RATING
1..100
5634
P/E GROWTH RATING
1..100
5100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INCR's Valuation (60) in the Servicestothe Health Industry industry is somewhat better than the same rating for RGC (95) in the Movies Or Entertainment industry. This means that INCR’s stock grew somewhat faster than RGC’s over the last 12 months.

INCR's Profit vs Risk Rating (100) in the Servicestothe Health Industry industry is in the same range as RGC (100) in the Movies Or Entertainment industry. This means that INCR’s stock grew similarly to RGC’s over the last 12 months.

INCR's SMR Rating (87) in the Servicestothe Health Industry industry is in the same range as RGC (100) in the Movies Or Entertainment industry. This means that INCR’s stock grew similarly to RGC’s over the last 12 months.

RGC's Price Growth Rating (34) in the Movies Or Entertainment industry is in the same range as INCR (56) in the Servicestothe Health Industry industry. This means that RGC’s stock grew similarly to INCR’s over the last 12 months.

INCR's P/E Growth Rating (5) in the Servicestothe Health Industry industry is significantly better than the same rating for RGC (100) in the Movies Or Entertainment industry. This means that INCR’s stock grew significantly faster than RGC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCRRGC
RSI
ODDS (%)
Bearish Trend 4 days ago
82%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
77%
Bullish Trend 4 days ago
84%
Momentum
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
84%
MACD
ODDS (%)
Bearish Trend 4 days ago
84%
N/A
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
71%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 18 days ago
73%
Bullish Trend 12 days ago
84%
Declines
ODDS (%)
Bearish Trend 5 days ago
80%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
INCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AGGNX23.830.64
+2.76%
American Century Global Gold I
NEEGX58.260.56
+0.97%
Needham Growth Retail
CGFFX84.440.20
+0.24%
American Funds Growth Fund of Amer 529F
MIGOX31.77-0.15
-0.47%
Marsico Global Institutional
FGTAX28.74-0.20
-0.69%
Fidelity Advisor Mega Cap Stock A

INCR and

Correlation & Price change

A.I.dvisor tells us that INCR and PHCUF have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INCR and PHCUF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCR
1D Price
Change %
INCR100%
+0.27%
PHCUF - INCR
26%
Poorly correlated
N/A
AKAN - INCR
23%
Poorly correlated
-2.54%
TLRY - INCR
22%
Poorly correlated
+3.48%
QNTM - INCR
22%
Poorly correlated
-1.64%
CGC - INCR
21%
Poorly correlated
+5.80%
More

RGC and

Correlation & Price change

A.I.dvisor tells us that RGC and CLCFF have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RGC and CLCFF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGC
1D Price
Change %
RGC100%
+3.27%
CLCFF - RGC
21%
Poorly correlated
-1.46%
QNTM - RGC
21%
Poorly correlated
-1.64%
SBFM - RGC
20%
Poorly correlated
-5.24%
CPHI - RGC
15%
Poorly correlated
+16.32%
INCR - RGC
8%
Poorly correlated
+0.27%
More